Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424655 | 1.00 | ALDH1A1 (0.32) | ALDH1A1LMNA | |
| SCHEMBL890790 | 0.76 | LMNA (0.53) | ALDH1A1LMNA | |
| SCHEMBL13694503 | 0.74 | LMNA (0.50) | ALDH1A1LMNA | |
| SCHEMBL1860323 | 0.74 | LMNA (0.50) | ALDH1A1LMNA | |
| SCHEMBL17077897 | 0.73 | — | — | |
| SCHEMBL3731363 | 0.71 | AKR1B1 (0.36) | ALDH1A1LMNA | |
| SCHEMBL1275073 | 0.71 | ARG1 (0.48) | ALDH1A1 | |
| SCHEMBL788419 | 0.71 | ARG1 (0.48) | ALDH1A1 | |
| SCHEMBL788420 | 0.71 | ARG1 (0.48) | ALDH1A1 | |
| SCHEMBL2056977 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567336-B2 | Conjugated TLR7 and/or TLR8 and TLR2 agonists | INVIVOGEN (FR) | 2017-02-14 | — | — | US | disclosed |
| EP-2769738-B1 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists | INVIVOGEN (FR) | 2016-07-20 | — | — | EP | disclosed |
| EP-2732825-B1 | Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist | INVIVOGEN (FR) | 2015-07-01 | — | — | EP | disclosed |
| EP-2769738-A1 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists | Invivogen (FR) | 2014-08-27 | — | — | EP | disclosed |
| US-20140141033-A1 | CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS | CAYLA (FR) | 2014-05-22 | — | — | US | disclosed |
| EP-2732825-A1 | Conjugated TLR7 and/or TLR8 and TLR2 agonists | Invivogen (FR) | 2014-05-21 | — | — | EP | disclosed |
| US-7795223-B2 | Treatment of inflammatory airway disease | NOVOZYMES BIOPHARMA AU LTD. (AU) | 2010-09-14 | — | — | US | disclosed |
| US-20080200394-A1 | Treatment of Inflammatory Airway Disease | GROPEP LIMITED (AU) | 2008-08-21 | — | — | US | disclosed |
| EP-1755635-A1 | TREATMENT OF INFLAMMATORY AIRWAY DISEASE | GroPep Limited (AU) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005115430-A1 | TREATMENT OF INFLAMMATORY AIRWAY DISEASE | GROPEP LIMITED (AU) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141033-A1 | CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS | TLR7, TLR8, TLR9 | ALDH1A1 4696/4885LMNA 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.